evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

93 questions · 97 findings · 12 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 13 · 13.4%GRADE not reported 0 · 0%Very low 38 · 39.2%Low 20 · 20.6%Moderate 24 · 24.7%High 2 · 2.1%

Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues

Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).

1 finding from 1 review

Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues

Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).

1 finding from 1 review

Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues

Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).

1 finding from 1 review